Medical/Pharmaceuticals

Besins Healthcare Unveils State-of-the-Art Hormone Factory in Muel, Spain, Amplifying Global Production Capabilities by 30%

"A Milestone in European Pharmaceutical Manufacturing": Besins Healthcare Debuts Pioneering Plant to Address Soaring Global Demand for Hormones and to Fortify Europe's Medical Sovereignty MONACO, Sept. 27, 2023 /PRNewswire/ -- Besins Healthcare, a global lead in Women's and Men's Reproductive He...

2023-09-27 15:56 1647

Seven AI/ML for Life Sciences Companies Identified as Innovators in New Clarivate Companies to Watch Report

Rapid acceleration in IP creation and scientific knowledge drives growing acceptance of AI and ML in drug discovery and development United States and Mainland China continue to lead innovation and remain at the forefront of AI technology advancement for drug discovery LONDON, Sept. 27, 2023 /PRN...

2023-09-27 15:00 1744

HRH Princess Astrid of Belgium visits Telix's New European Manufacturing Facility in Brussels South

MELBOURNE, Australia and LIEGE, Belgium, Sept. 27, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) has welcomed Her Royal Highness,Princess Astrid, Princess of Belgium to Telix Manufacturing Solutions (TMS), the Company's recently inaugurated production facility,...

2023-09-27 12:00 2147

'Bayer For Her' Supporting 365 Days Conversations of Care to More Women in Asia

* Bridging the gap on lack of discussion amongst Asian women on their health concerns this World Contraception Day (WCD) SINGAPORE, Sept. 27, 2023 /PRNewswire/ -- Bayer Pharmaceuticals Division inAsia/Pacific announced today in conjunction with World Contraception Day, the inception of its 'Bay...

2023-09-27 10:00 2271

Remegen's Innovative New Drug Telitacicept(RC18) Obtains Positive Phase III Results, Submitted for Second Indication for Treatment of Rheumatoid Arthritis

YANTAI, China, Sept. 27, 2023 /PRNewswire/ -- RemeGen Co., Ltd.  ("RemeGen" or "the Company") (HKG: 9995, SHA: 688331), a fully-integrated commercial-stage biotechnology company, recently announced that Telitacicept(RC18) for injection obtained positive results in a Phas...

2023-09-27 09:30 3347

SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data on IKZF2 Protein Degrader Program and MOPED™ Molecular Glue Screening Platform at the 20th Annual Discovery on Target Conference

These are the first in a series of presentations scheduled through the end of the year sharing advances to SK Biopharmaceutical's targeted protein degradation (TPD) pipeline SEOUL, South Korea and KING OF PRUSSIA, Pa., Sept. 26, 2023 /PRNewswire/ -- SK Biopharmaceuticals, a global biotech focuse...

2023-09-27 08:30 1497

ABM Therapeutics' ABM-1310 Granted Fast Track Designation by the FDA Following Orphan Drug Designation

SAN DIEGO and SHANGHAI, Sept. 26, 2023 /PRNewswire/ -- ABM Therapeutics is pleased to announce today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the investigation of ABM-1310 for the treatment of Glioblastoma (GBM) patients carrying BRAF V600E mutation,...

2023-09-27 00:00 1767

Latest Updates of Viva's Portfolio Companies

HONG KONG, Sept. 26, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the su...

2023-09-26 21:06 1808

China Jo-Jo Drugstores Announces $2.59 Million Registered Direct Offering

HANGZHOU, China, Sept. 26, 2023 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that it ...

2023-09-26 21:00 3323

Actinogen optimizes XanaMIA Phase 2b Alzheimer's disease trial design and provides general business update

Highlights Changes to the XanaMIA protocol reduce cost by AUD 30 million over the next two years and speed time to initial results while preserving the 36-week design and trial endpoints. UK sites added to the XanaCIDD trial of cognitive impairment associated with depression, due to report resu...

2023-09-26 20:51 1520

YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine

GAITHERSBURG, Md., Sept. 26, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious dise...

2023-09-26 20:30 1581

WuXi Vaccines Launches Its First Vaccines CDMO Site in China

SUZHOU, China, Sept. 26, 2023 /PRNewswire/ -- WuXi Vaccines, a leading contract development and manufacturing organization (CDMO) focused on vaccine discovery, development, and manufacturing, has launched its first standalone vaccines CDMO site in Suzhou,China. The opening will add drug substanc...

2023-09-26 15:41 1484

Ascletis Announces Completion of Enrollment of 120 Patients in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

--Based on prespecified interim analysis condition, 120 patients are likely to lead sufficient events for interim analysis of progression-free survival (PFS) HANGZHOU and SHAOXING, China, Sept. 26, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces the completion o...

2023-09-26 08:10 2145

Johnson & Johnson Innovation Announces Collaboration with Singapore Economic Development Board to Help Transform Singapore's Life Science Innovation Ecosystem

The first-of-its-kind collaboration will embed the services and resources of Johnson & Johnson Innovation - JLABS intoSingapore's life science ecosystem to unlock regional innovation potential. SINGAPORE, Sept. 26, 2023 /PRNewswire/ -- Johnson & Johnson International ( Singapore) Pte. Ltd. today ...

2023-09-26 06:30 2375

Chime Biologics Enters into a Strategic Cooperation Agreement with Korea Kings Pharm to Accelerate the Biosimilar Launch

* Chime Biologics has entered into a strategic collaboration with Kings Pharm for a biosimilar asset, providing cell line development, process development, global GMP manufacturing, commercialization and regulatory filing support. Chime will also supply the commercial production once the produc...

2023-09-25 20:15 1490

Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology

SINGAPORE, Sept. 25, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore -based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunothera...

2023-09-25 19:00 1504

EQT PRIVATE EQUITY TO SELL LIMACORPORATE TO ENOVIS: THE ITALIAN SITE IN SAN DANIELE DEL FRIULI WILL REMAIN THE FULCRUM OF PRODUCTION, BENEFITING FROM NEW INVESTMENTS

UDINE, Italy, Sept. 25, 2023 /PRNewswire/ -- EQT Private Equity announces the sale of LimaCorporate to Enovis. With this transaction, LimaCorporate will become part of the NYSE-listed Enovis group in a strategic combination that creates a global leader in the orthopaedic industry. Founded in 194...

2023-09-25 18:01 2053

Huawei Accelerates Intelligent Healthcare with the Innovative Digital Medical Technology Solution

SHANGHAI, Sept. 25, 2023 /PRNewswire/ -- During HUAWEI CONNECT 2023, Huawei held the first intelligent healthcare summit themed "Build a Digital Health Community to Accelerate Intelligent Healthcare". Huawei released the Digital Medical Technology Solution to help the healthcare industry go smart...

2023-09-25 15:35 2178

"Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery"

SHENZHEN, China, Sept. 25, 2023 /PRNewswire/ -- On September 15, "Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery" successfully kicked off. This marks the first time in recent years that the Company has organized an event specifically focused on pharmaceutical R&D innovation. The...

2023-09-25 15:31 2070

Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology

CASTRES, France and CAMBRIDGE, England, Sept. 25, 2023 /PRNewswire/ -- Pierre Fabre Laboratories and Vernalis (R&D) Ltd ("Vernalis"), a fully owned subsidiary of HitGen Inc., are pleased to announce a long-term partnership to identify pre-clinical candidates against multiple oncology targets.   ...

2023-09-25 15:00 1511
1 ... 143144145146147148149 ... 611